N. Miyanaga et al., CLINICAL-EVALUATION OF NUCLEAR-MATRIX-PROTEIN-22 (NMP22) IN URINE AS A NOVEL MARKER FOR UROTHELIAL CANCER, European urology, 31(2), 1997, pp. 163-168
Objectives: This study was undertaken to determine the clinical useful
ness of nuclear matrix protein 22 (NMP22) as a novel urine marker for
urothelial cancer, particularly, to substitute for voided-urine cytolo
gy. Methods: NMP22 values were determined for 280 patients and 20 heal
thy volunteers by NMP22 Test Kit based on an enzyme-linked immunosorbe
nt assay. Results: When the cut-off value was set at 10 U/ml, the posi
tive rate of urinary NMP22 for urothelial cancer was 80.9% (38/47), wh
ereas that for posttreatment cases and benign diseases was 35.7% (74/2
07). When urinary NMP22 and voided-urine cytology were compared, the t
est for urinary NMP22 showed higher sensitivity than cytology in patie
nts with urothelial cancer. When urinary NMP22 values were determined
pre- and postoperatively in patients with urothelial cancer, the posto
perative value decreased in all patients, and were below the cut-off v
alue in all except one patient. Conclusions: Urinary NMP22 is a useful
diagnostic marker as a substitute for voided-urine cytology for the s
urveillance of urothelial cancer.